Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2
Numerous studies have reported the regulatory effects of miR-21-5p and reversine in human breast cancer (HBC). However, the mechanism of reversine and miR-21-5p has not been fully investigated in HBC. The aim of the current study was to assess the mechanism of action of reversine, with or without mi...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-01-01
|
| Series: | Bioengineered |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21655979.2021.2009410 |
| _version_ | 1798033985676247040 |
|---|---|
| author | Yue Zhang Yaoyi Wang Jun Xue Wanping Liang Zhisheng Zhang Xiuming Yang Zhifei Qiao Yang Jiang Junping Wang Xuchen Cao Peng Chen |
| author_facet | Yue Zhang Yaoyi Wang Jun Xue Wanping Liang Zhisheng Zhang Xiuming Yang Zhifei Qiao Yang Jiang Junping Wang Xuchen Cao Peng Chen |
| author_sort | Yue Zhang |
| collection | DOAJ |
| description | Numerous studies have reported the regulatory effects of miR-21-5p and reversine in human breast cancer (HBC). However, the mechanism of reversine and miR-21-5p has not been fully investigated in HBC. The aim of the current study was to assess the mechanism of action of reversine, with or without miR-21-5p, in HBC progression. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blot results confirmed the upregulation of miR-21-5p and downregulation of sprouty RTK signaling antagonist 2 (SPRY2) in HBC. Bioinformatics analysis and luciferase assay identified the correlation between miR-21-5p and SPRY2. Cell function experiment results indicated a decrease in migration, proliferation, and invasion of HBC cells treated with miR-21-5p inhibitor and reversine; however, an increase in apoptosis was observed in these cells. Apoptotic ability was more enhanced and migration, proliferation, and invasion were more impaired in HBC cells treated with both miR-21-5p inhibitor and reversine than in those treated individually with either inhibitors. SPRY2, downstream of miR-21-5p, participated in HBC progression with reversine. Overall, our study proved that combining the miR-21-5p inhibitor with reversine produced a synergistic effect by regulating SPRY2, thereby limiting HBC progression. This knowledge might offer insights into the clinical therapy of HBC. |
| first_indexed | 2024-04-11T20:37:59Z |
| format | Article |
| id | doaj.art-8e4633c2767f4d3b87f4a3aeeba0bd92 |
| institution | Directory Open Access Journal |
| issn | 2165-5979 2165-5987 |
| language | English |
| last_indexed | 2024-04-11T20:37:59Z |
| publishDate | 2022-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Bioengineered |
| spelling | doaj.art-8e4633c2767f4d3b87f4a3aeeba0bd922022-12-22T04:04:19ZengTaylor & Francis GroupBioengineered2165-59792165-59872022-01-0113145546810.1080/21655979.2021.20094102009410Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2Yue Zhang0Yaoyi Wang1Jun Xue2Wanping Liang3Zhisheng Zhang4Xiuming Yang5Zhifei Qiao6Yang Jiang7Junping Wang8Xuchen Cao9Peng Chen10Tianjin Medical University Cancer Institute and HospitalTianjin Medical University General HospitalThe First Affiliated Hospital of Hebei North UniversityThe First Affiliated Hospital of Hebei North UniversityThe First Affiliated Hospital of Hebei North UniversityThe First Affiliated Hospital of Hebei North UniversityThe First Affiliated Hospital of Hebei North UniversityThe First Affiliated Hospital of Hebei North UniversityTianjin Medical University General HospitalNational Clinical Research Center for CancerTianjin Medical University Cancer Institute and HospitalNumerous studies have reported the regulatory effects of miR-21-5p and reversine in human breast cancer (HBC). However, the mechanism of reversine and miR-21-5p has not been fully investigated in HBC. The aim of the current study was to assess the mechanism of action of reversine, with or without miR-21-5p, in HBC progression. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blot results confirmed the upregulation of miR-21-5p and downregulation of sprouty RTK signaling antagonist 2 (SPRY2) in HBC. Bioinformatics analysis and luciferase assay identified the correlation between miR-21-5p and SPRY2. Cell function experiment results indicated a decrease in migration, proliferation, and invasion of HBC cells treated with miR-21-5p inhibitor and reversine; however, an increase in apoptosis was observed in these cells. Apoptotic ability was more enhanced and migration, proliferation, and invasion were more impaired in HBC cells treated with both miR-21-5p inhibitor and reversine than in those treated individually with either inhibitors. SPRY2, downstream of miR-21-5p, participated in HBC progression with reversine. Overall, our study proved that combining the miR-21-5p inhibitor with reversine produced a synergistic effect by regulating SPRY2, thereby limiting HBC progression. This knowledge might offer insights into the clinical therapy of HBC.http://dx.doi.org/10.1080/21655979.2021.2009410human breast cancerreversinemir-21-5pspry2 |
| spellingShingle | Yue Zhang Yaoyi Wang Jun Xue Wanping Liang Zhisheng Zhang Xiuming Yang Zhifei Qiao Yang Jiang Junping Wang Xuchen Cao Peng Chen Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2 Bioengineered human breast cancer reversine mir-21-5p spry2 |
| title | Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2 |
| title_full | Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2 |
| title_fullStr | Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2 |
| title_full_unstemmed | Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2 |
| title_short | Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2 |
| title_sort | co treatment with mir 21 5p inhibitor and aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty rtk signaling antagonist 2 |
| topic | human breast cancer reversine mir-21-5p spry2 |
| url | http://dx.doi.org/10.1080/21655979.2021.2009410 |
| work_keys_str_mv | AT yuezhang cotreatmentwithmir215pinhibitorandaurorakinaseinhibitorreversinesuppressesbreastcancerprogressionbytargetingsproutyrtksignalingantagonist2 AT yaoyiwang cotreatmentwithmir215pinhibitorandaurorakinaseinhibitorreversinesuppressesbreastcancerprogressionbytargetingsproutyrtksignalingantagonist2 AT junxue cotreatmentwithmir215pinhibitorandaurorakinaseinhibitorreversinesuppressesbreastcancerprogressionbytargetingsproutyrtksignalingantagonist2 AT wanpingliang cotreatmentwithmir215pinhibitorandaurorakinaseinhibitorreversinesuppressesbreastcancerprogressionbytargetingsproutyrtksignalingantagonist2 AT zhishengzhang cotreatmentwithmir215pinhibitorandaurorakinaseinhibitorreversinesuppressesbreastcancerprogressionbytargetingsproutyrtksignalingantagonist2 AT xiumingyang cotreatmentwithmir215pinhibitorandaurorakinaseinhibitorreversinesuppressesbreastcancerprogressionbytargetingsproutyrtksignalingantagonist2 AT zhifeiqiao cotreatmentwithmir215pinhibitorandaurorakinaseinhibitorreversinesuppressesbreastcancerprogressionbytargetingsproutyrtksignalingantagonist2 AT yangjiang cotreatmentwithmir215pinhibitorandaurorakinaseinhibitorreversinesuppressesbreastcancerprogressionbytargetingsproutyrtksignalingantagonist2 AT junpingwang cotreatmentwithmir215pinhibitorandaurorakinaseinhibitorreversinesuppressesbreastcancerprogressionbytargetingsproutyrtksignalingantagonist2 AT xuchencao cotreatmentwithmir215pinhibitorandaurorakinaseinhibitorreversinesuppressesbreastcancerprogressionbytargetingsproutyrtksignalingantagonist2 AT pengchen cotreatmentwithmir215pinhibitorandaurorakinaseinhibitorreversinesuppressesbreastcancerprogressionbytargetingsproutyrtksignalingantagonist2 |